Clinical trials: Eicosapentaenoic Acid
Whole Body Energy Metabolism
Effects of 12 Weeks of Omega 3 Supplementation on Resting Metabolic Rate
Fatty acids are the main components of the cell membranes. It has been demonstrated that diet can alter the characteristics and function of many membranes in the body, which has an effect on cardiovascular and metabolic health.
- Trial name
- NCT02092649
- Testing
- Omega-3 Complete
- Where
- Canada
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Guelph
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
This randomized phase II trial studies how well docosahexaenoic acid works in preventing recurrence in breast cancer survivors. Docosahexaenoic acid supplement may prevent recurrence in breast cancer survivors.
- Conditions
- Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ
- Trial name
- NCT01849250
- Testing
- Docosahexaenoic Acid
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Healthy Volunteers
Influence of Dietary Omega-3 Fatty Acids in Various triOMEG Sausages on the HS-Omega-3 Index in Healthy Individuals
New approaches to increase eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in our diet are needed, but any new approach needs to demonstrate the bioavailability of EPA+DHA, and its safety and palatability.
- Trial name
- NCT02148835
- Testing
- Sausage: Triomeg, Sausage: Control
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Clemens von Schacky
Familial Adenomatous Polyposis Coli, FAP
Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA
This purpose of this study is to investigate whether the number and size of rectal polyps can be reduced in patients with Familial Adenomatous Polyposis (FAP) by using a highly-purified form of a naturally occurring substance…
- Trial name
- NCT00510692
- Testing
- Eicosapentanoic Acid (EPA), Endoscopy, Biopsies taken
- Where
- United Kingdom
- Volunteers
- 58 people
- Sponsor
- S.L.A. Pharma AG
Epilepsy
Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures
The purpose of this study is to determine if Omega-3 fatty acids reduce seizures and modify cardiac risk factors in people with epilepsy.
- Trial name
- FOS (NCT00871377)
- Testing
- High Dose Fish Oil, Low Dose Fish Oil
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Hypertriglyceridemia
Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides
The purpose of this study is to evaluate the cardiovascular and lipid effects of two doses of an omega-3 fatty acid concentrate in a group of people who normally are not treated for high lipids.
- Trial name
- OMEGA (NCT00504309)
- Testing
- 4/day of 4g P-OM3 capsules, 4/day of 1g P-OM3 capsules
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Penn State University
Cancer Cachexia
A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia
The data collected through this pilot study will allow us to increase our understanding of cancer cachexia and the effect of Eicosapentaenoic Acid (EPA) on cancer cachexia.
- Trial name
- NCT00815685
- Testing
- Eicosapentaenoic Acid
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pregnancy
Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes
DHA, a type of fatty acid, is important in early development, both in terms of reproductive physiology of gestation and in postnatal behavioral and cognitive function.
- Trial name
- NCT01007110
- Testing
- DHA
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of Kansas
Respiratory Distress Syndrome, Adult, Acute Lung Injury
A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)
The purpose of this study is to determine whether fish oil (containing omega-3 fatty acids) given enterally is safe and effective in reducing lung and systemic inflammation seen in acute lung injury.
- Conditions
- Respiratory Distress Syndrome, Adult, Acute Lung Injury, Acute Respiratory Distress Syndrome
- Trial name
- NCT00351533
- Testing
- Fish oil (eicosapentaenoic acid and docosahexanoic acid)
- Where
- 5 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- University of Washington
Obesity, Inflammation
Effects of DHA on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment
Comparative, randomized, placebo-controlled, single-centre, single-blind clinical trial to assess the effectiveness of providing additional DHA omega-3 fatty acids supplements to increase the levels of pro-resolving and…
- Trial name
- NCT01865448
- Testing
- Omega-3 DHA
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- Protein Supplies SL
Metabolic Syndrome
Role of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Inflammation and Lipids
The objective of this study is to provide critical information regarding both common and distinctive roles of EPA and DHA in systemic inflammation and lipid metabolism.
- Trial name
- NCT02670382
- Testing
- EPA, DHA, sunflower oil
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tufts University
Chronic Myeloid Leukemia, Chronic Phase
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
This is a Phase I/II single site, open label clinical trial. The purpose of the Phase I portion is to determine the safety, tolerability, and recommended Phase II dose of Eicosapentaenoic Acid (EPA) when given daily in…
- Trial name
- NCT04006847
- Testing
- Eicosapentaenoic Acid, Tyrosine kinase inhibitor
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Milton S. Hershey Medical Center
Attention Deficit Disorder
Effect of Omega-3 Fatty Acid on Cortical Function in ADHD
The study hypothesis is that DHA is more effective than placebo in increasing brain activation and reducing symptoms in psychostimulant-free children with ADHD.
- Trial name
- NCT01883817
- Testing
- DHA Omega-3
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Cincinnati
Major Depression, Cancer
Omega 3 FA Supplements as Augmentation in the Treatment of Depression
To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions…
- Conditions
- Major Depression, Cancer, Diabetes, Cardiovascular Diseases
- Trial name
- NCT01803711
- Testing
- Desvenlafaxine, Omega 3 Fatty acids
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- UConn Health
Severe Hypertriglyceridemia
Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation
The objectives of this study are to compare the relative bioavailabilities of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of Epanova or Lovaza during periods of high- and low -fat…
- Trial name
- ECLIPSE (NCT01208961)
- Testing
- Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Age-related Macular Degeneration, Cataract
Age-Related Eye Disease Study 2 (AREDS2)
Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant vitamins C and E, beta carotene, and zinc) has been shown to reduce the risk of progression to advanced age-related macular degeneration…
- Trial name
- AREDS2 (NCT00345176)
- Testing
- Lutein/zeaxanthin, DHA/EPA, Lutein/zeaxanthin and DHA/EPA
- Where
- 91 sites in United States
- Volunteers
- 4,203 people
- Sponsor
- National Eye Institute (NEI)
Muscular Dystrophy, Duchenne
Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB Patients
The purpose of this study is to evaluate the effect of docosahexaenoic fatty acid and eicosapentaenoic fatty acid supplementation for six months on the inflammation state as well as the process of muscular regeneration and the…
- Trial name
- NCT01826422
- Testing
- EPA and DHA
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Hypertriglyceridemia
Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)
The primary objective is to determine the efficacy of AMR101 (ethyl icosapentate) compared to placebo in lowering high fasting triglyceride levels in patients with high risk for cardiovascular disease and fasting triglyceride…
- Trial name
- ANCHOR (NCT01047501)
- Testing
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day
- Where
- 80 sites in United States
- Volunteers
- 702 people
- Sponsor
- Amarin Pharma Inc.
Cystic Fibrosis
Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults
An International Phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of LAU-7b administered once-daily for 6 months for the treatment of CF.
- Trial name
- APPLAUD (NCT03265288)
- Testing
- LAU-7b
- Where
- 40 sites in United States, Australia and 1 more
- Volunteers
- 166 people
- Sponsor
- Laurent Pharmaceuticals Inc.